“Introduction of counterfeit products in the normal international supply chain poses particular issues for pharmaceutical companies, both from direct risk to their customers and to their own reputation within what is a highly competitive industry,” cautions Charles A. Smith, senior systems consultant at Horizon. “There is a direct cost of product recall, where positive identification of counterfeits can be difficult, without the identification and data handling capabilities provided by serialization.”
Experts from Optel Vision and NJM Packaging spoke about preparing packaging lines for item-level serialization during an hour-long conference at Pack Expo Las Vegas on September 24. Jean-Pierre Allard from Optel Vision and Dan Lapierre from NJM Packaging discussed packaging line integration challenges and possible solutions.
The California State Board of Pharmacy will be holding an E-Pedigree Committee Meeting in El Segundo, CA, on September 26, 2013. The meeting is open to the public and it will also be broadcast via a Webcast.
The CA BoP reports it will address the following:
As drug manufacturers take steps to comply with serialization requirements around the globe, they may also be able to benefit from the significant amounts of data generated by serialization. So argued Peter Schmitt, managing associate of Montesino Associates LLC, who spoke on the opening day of Pharmapack North America in Philadelphia.
Pharma serialization provider Systech International is partnering with Tata Consultancy Services (TCS), a provider of IT services and business solutions, to offer life sciences companies "an effective and economic means of implementing serialization programs," it reported in a statement.
By Steve Wood
President and CEO, Covectra
Over the last few years, prescription drug diversion and abuse has grown at alarming rates, resulting in an increase in the number of deaths and hospitalizations. Opioid addiction and abuse has become one the nation’s most serious healthcare crises. More than 23,000 people die each year from prescription drug abuse—more than are killed in traffic incidents.